Trial Profile
Efficacy of therapeutic drug monitoring of mTOR inhibitor (Everolimus) in patients with renal cell carcinoma
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2014
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Pharmacokinetics; Therapeutic Use
- 02 Oct 2013 New trial record